Next Article in Journal
External Beam Radiotherapy of Recurrent Glioma: Radiation Tolerance of the Human Brain
Next Article in Special Issue
Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials
Previous Article in Journal
Remodeling of Tumor Stroma and Response to Therapy
Previous Article in Special Issue
Micronutrient Synergy in the Fight against Hepatocellular Carcinoma
Review

A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase

1
Department of Biology, University of Tor Vergata, Rome 00133, Italy
2
Laboratory of Cell Signaling, Santa Lucia Foundation-IRCCS, Rome 00179, Italy
*
Author to whom correspondence should be addressed.
Cancers 2012, 4(2), 354-378; https://doi.org/10.3390/cancers4020354
Received: 13 February 2012 / Revised: 15 March 2012 / Accepted: 26 March 2012 / Published: 5 April 2012
(This article belongs to the Special Issue Advances and Research Progress in Hepatocellular Carcinoma)
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. HCCs are genetically and phenotypically heterogeneous tumors characterized by very poor prognosis, mainly due to the lack, at present, of effective therapeutic options, as these tumors are rarely suitable for radiotherapy and often resistant to chemotherapy protocols. In the last years, agonists targeting the Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) death receptor, has been investigated as a valuable promise for cancer therapy, based on their selectivity for malignant cells and low toxicity for healthy cells. However, many cancer models display resistance to death receptor induced apoptosis, pointing to the requirement for the development of combined therapeutic approaches aimed to selectively sensitize cancer cells to TRAIL. Recently, we identified ATM kinase as a novel modulator of the ability of chemotherapeutic agents to enhance TRAIL sensitivity. Here, we review the biological determinants of HCC responsiveness to TRAIL and provide an exhaustive and updated analysis of the molecular mechanisms exploited for combined therapy in this context. The role of ATM kinase as potential novel predictive biomarker for combined therapeutic approaches based on TRAIL and chemotherapeutic drugs will be closely discussed. View Full-Text
Keywords: ATM kinase; hepatocellular carcinoma; TRAIL; combined therapy ATM kinase; hepatocellular carcinoma; TRAIL; combined therapy
Show Figures

Figure 1

MDPI and ACS Style

Stagni, V.; Santini, S.; Barilà, D. A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase. Cancers 2012, 4, 354-378. https://doi.org/10.3390/cancers4020354

AMA Style

Stagni V, Santini S, Barilà D. A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase. Cancers. 2012; 4(2):354-378. https://doi.org/10.3390/cancers4020354

Chicago/Turabian Style

Stagni, Venturina, Simonetta Santini, and Daniela Barilà. 2012. "A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase" Cancers 4, no. 2: 354-378. https://doi.org/10.3390/cancers4020354

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop